DAPASIG M 10 10

About

DAPASIG M 10, a combination of dapagliflozin and metformin, is a medication used to improve glycemic control in adults with type 2 diabetes mellitus. Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine. Metformin, a biguanide, primarily works by reducing hepatic glucose production, decreasing intestinal glucose absorption, and improving insulin sensitivity in peripheral tissues. The combination of these two agents provides complementary mechanisms of action to effectively lower blood glucose levels. This dual therapy offers comprehensive glycemic control, with additional benefits such as potential weight reduction and the established cardiovascular and renal protective effects associated with dapagliflozin. The 10mg refers to the dapagliflozin component, while the metformin dosage would be specified separately (e.g., 500mg, 850mg, 1000mg).

Uses

• Improvement of glycemic control in type 2 diabetes mellitus.
• Adjunct to diet and exercise for blood sugar management.
• Reduction of HbA1c levels.
• May contribute to weight management in diabetic patients.

Directions For Use

Take orally, usually twice daily with meals, as directed by your healthcare provider.

Benefits

• Comprehensive blood glucose control.
• Reduces HbA1c effectively.
• May lead to modest weight loss.
• Offers cardiovascular and renal protection.
• Improves insulin sensitivity.
• Reduces hepatic glucose production.

Side Effects

• Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)
• Genital mycotic infections
• Urinary tract infections
• Increased urination
• Hypoglycemia (especially with other diabetes meds)
• Lactic acidosis (rare, but serious with metformin)
• Vitamin B12 deficiency (with metformin)
• Headache
• Dizziness
• Thirst
• Metallic taste (with metformin)
• Rash

Safety Measures

• Alcohol - Avoid excessive alcohol intake due to increased risk of lactic acidosis (with metformin) and hypoglycemia.
• Pregnancy - Not recommended during pregnancy; insulin is generally preferred for glycemic control in pregnant women.
• Breastfeeding - Not recommended during breastfeeding as both components may pass into breast milk.
• Liver - Metformin is contraindicated in severe hepatic impairment; dapagliflozin requires caution in severe impairment.
• Kidney - Metformin is contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²); dapagliflozin requires dose adjustment or is not recommended below certain eGFR thresholds.
• Lung - Use with caution in conditions causing hypoxia, as this may increase the risk of lactic acidosis with metformin.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.